Gilead Sciences Inc (GILD) Stock Price, Quote & News

Company Profile

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Descovy, Genvoya, Odefsey, Sunlenca, Symtuza, and YeztugoFor the treatment of HIV-1 infection in patients. It also provides Epclusa, Livdelzi, and Vemlidy to treat chronic hepatitis C virus, primary biliary cholangitis, and chronic hepatitis B virus; Tecartus, a T-cell therapy for...

Industry: Drug Manufacturers - General

Sector: Healthcare

Phone: 650 574 3000

Fax: 650 522 5853

Website: www.gilead.com

Address:

333 Lakeside Drive, Foster City, United States

notreload_ai Apr. 7 at 8:01 PM

$GILD to acquire Tubulis for up to $5 billion, validating the ADC space. Leerink sees major tailwind for $STRO and initiates coverage with $38 price target. https://notreload.xyz/xy/gilead-tubulis-deal-boosts-sutro-biopharma/

0 · Reply

StocktwitsNews Apr. 7 at 7:29 PM

Gilead-Tubulis $5B Deal Gives STRO Stock A Boost — Here’s Why $STRO $GILD https://stocktwits.com/news/equity/markets/gilead-tubulis-5b-deal-gives-stro-stock-a-boost-here-why/cZJBRoxRIqc

0 · Reply

RadioIsotope25 Apr. 7 at 5:46 PM

Gilead loading $GILD in ADC’s they need radio ADC’s at $RADX

0 · Reply

notreload_ai Apr. 7 at 12:55 PM

$GILD buys German biotech Tubulis for $3.15B to boost cancer-fighting “smart” drugs called ADCs. Deal closes Q2 2026. https://notreload.xyz/xy/gilead-acquires-tubulis-in-adc-oncology-deal/

0 · Reply

EdwardGonza Apr. 7 at 12:54 PM

$GILD Gilead Sciences has reached an agreement to acquire the German ADC specialist Tubulis to bolster its oncology pipeline with next-generation payloads and platforms. The transaction, valued at approximately $3.15 billion, brings clinical programs TUB-040 and TUB-030 into Gilead's portfolio, among other assets, and establishes the Munich site as a central ADC innovation hub within the company. The deal is expected to close in the second quarter of 2026.

0 · Reply

OpenOutcrier Apr. 7 at 12:31 PM

$GILD (-0.8% pre) Gilead To Buy Tubulis For $3.15B Cash, Up To $1.85B Contingent - Bloomberg https://ooc.bz/l/98118

0 · Reply

55X_ROI_Q1_2026 Apr. 7 at 4:38 AM

$SLS SLS009 Published BETTER Phase 2B Data at ASH, than the Phase 1B data $FTSV Published, which was the basis for the $GILD $4.9B Buyout. SLS's Secondary Asset is right now worth More than 6x the entire Current SLS Market Cap.

0 · Reply

55X_ROI_Q1_2026 Apr. 7 at 4:15 AM

$SLS We are happy right now. Right Now. SLS009 Phase 2B AML-Mr data published at ASH is better than $FTSV Magrolimab Ph1B AML-Mr data published at ASH, that caused $GILD to buy it for $4.9B.

1 · Reply

trenddetector Apr. 6 at 4:03 PM

$GILD Share this site with anyone that has cancer, or has a friend or family member with cancer, and is searching for options. A great resource for those confused about approved treatments and trials that are enrolling. https://nimble-frangollo-81ff5e.netlify.app/#

0 · Reply

TILResearch Apr. 4 at 5:13 AM

$GILD cured Hepatitis C and destroyed its own $19B franchise in the process. Now it's sitting on a $14.3B/year HIV drug, $10B in annual operating cash flow, and $30B+ in acquisitions trying to build the next act. New deep dive: https://www.theinvestmentlog.com/posts/gild/2026-04-04

0 · Reply

EQT Life Sciences to exit minority stake in Tubulis via sale to Gilead Sciences for up to USD 5.0 billion

Apr 7, 2026, 9:14 AM EDT - 10 hours ago

Gilead Adds to Cancer Pipeline With Acquisition Worth Up to $5 Billion

Apr 7, 2026, 8:50 AM EDT - 10 hours ago

Gilead Sciences to Buy Clinical-Stage Biotech Tubulis for Up to $5 Billion

Apr 7, 2026, 8:30 AM EDT - 10 hours ago

Gilead to Acquire Tubulis Adding Potentially Best-in-Class Antibody-Drug Conjugate and Next Generation Platform to Further Strengthen Oncology Pipeline

Apr 7, 2026, 8:23 AM EDT - 10 hours ago

Gilead to acquire Tubulis GmbH for up to $5 billion

Apr 1, 2026, 4:13 PM EDT - 6 days ago

Gilead Extends Tender Offer to Acquire Arcellx

Apr 1, 2026, 10:50 AM EDT - 6 days ago

Markets Haven't Changed. These 2 Cheap Dividends Still Rule

Mar 24, 2026, 8:03 AM EDT - 14 days ago

Gilead to Buy Ouro Medicines for $2.2 Billion. ‘Immune Reset' Is Key to Future Gains.

Mar 23, 2026, 6:55 PM EDT - 15 days ago

Gilead Sciences to Buy Ouro Medicines for Up to $2.18 Billion

Mar 23, 2026, 6:28 PM EDT - 15 days ago

Gilead to buy biotech firm Ouro Medicines in over $2 billion deal

Mar 23, 2026, 6:15 PM EDT - 15 days ago

Gilead Sciences to Acquire Ouro Medicines to Advance First in Class T Cell Engager Program for Autoimmune Diseases

Mar 23, 2026, 12:44 PM EDT - 15 days ago

Gilead nearing up to $2 billion buyout of biotech Ouro Medicines, FT reports

Mar 19, 2026, 2:15 PM EDT - 19 days ago

5 Stocks to Buy in a High-Risk Bull Market

AAPL C JCI PYPL

Mar 18, 2026, 2:23 PM EDT - 20 days ago

TrumpRx lists many medicines at prices higher than paid in UK

ABBV AMGN AZN BMY GSK JNJ LLY

Mar 5, 2026, 1:02 AM EST - 4 weeks ago

South Africa seeks local production of Gilead's HIV prevention drug

Mar 2, 2026, 8:30 AM EST - 5 weeks ago

Gilead Foundation Awards $12 Million to Empower Community Health Workers and Expand HIV Prevention Initiatives Across 14 States and the District of Columbia

Feb 27, 2026, 2:30 PM EST - 5 weeks ago

Johanna Mercier on Gilead's HIV prevention innovation

Feb 25, 2026, 2:27 PM EST - 5 weeks ago

Gilead's experimental HIV treatment shows low discontinuation rates in studies

Feb 25, 2026, 1:44 PM EST - 5 weeks ago

Gilead's Single-Tablet Regimen of Bictegravir and Lenacapavir Maintained Virological Suppression in People With HIV Who Switched Antiretroviral Therapy

Feb 23, 2026, 4:05 PM EST - 6 weeks ago

Gilead Sciences to Present at Upcoming Investor Conferences

Feb 23, 2026, 8:41 AM EST - 6 weeks ago

Why is Arcellx stock up 80% today? Gilead's $7.8B answer

ACLX

Feb 23, 2026, 7:52 AM EST - 6 weeks ago

Gilead to acquire cancer therapy developer Arcellx for up to $7.8 billion

ACLX

Feb 23, 2026, 7:13 AM EST - 6 weeks ago

Gilead shows its belief in its partner's cancer treatment with a $7.8 billion buyout

Feb 23, 2026, 6:36 AM EST - 6 weeks ago

Gilead Sciences to Buy Arcellx in Deal Valued at $7.8 Billion

ACLX

Feb 23, 2026, 6:34 AM EST - 6 weeks ago

This Biotech Stock Is Surging 80%. Gilead Sciences Has Agreed to Buy It.

Feb 23, 2026, 6:08 AM EST - 6 weeks ago

Gilead to acquire Arcellx for $7.8 billion

ACLX

Feb 23, 2026, 6:01 AM EST - 6 weeks ago

Gilead Sciences to Acquire Arcellx to Maximize Long-term Potential of Anito-cel

ACLX

Feb 23, 2026, 6:01 AM EST - 6 weeks ago

Gilead Sciences to Acquire Arcellx to Maximize Long-Term Potential of Anito-cel

ACLX

Feb 17, 2026, 8:30 AM EST - 7 weeks ago

Gilead to Present New HIV Treatment and Prevention Data at CROI 2026, With a Focus on Expanding Options

Feb 11, 2026, 8:53 AM EST - 7 weeks ago

Gilead Analysts Boost Their Forecasts After Upbeat Q4 Earnings

Feb 10, 2026, 5:56 PM EST - 2 months ago

Gilead Stock Slips After Q4 Earnings, Weak FY26 Guidance

Feb 10, 2026, 4:39 PM EST - 2 months ago

Gilead Sciences Profit Rises on Growth of Liver Disease, HIV Products

Feb 10, 2026, 4:07 PM EST - 2 months ago

Gilead quarterly results beat Wall Street estimates

Feb 10, 2026, 4:02 PM EST - 2 months ago

Gilead Sciences Announces 3.8 Percent Increase in First Quarter 2026 Dividend

Feb 10, 2026, 4:01 PM EST - 2 months ago

Gilead Sciences Announces Fourth Quarter and Full Year 2025 Financial Results

$FDA Approves Label Update for Kite's Yescarta® for Relapsed/Refractory Primary Central Nervous System Lymphoma$

Feb 6, 2026, 8:30 AM EST - 2 months ago

FDA Approves Label Update for Kite's Yescarta® for Relapsed/Refractory Primary Central Nervous System Lymphoma

Jan 27, 2026, 4:05 PM EST - 2 months ago

Gilead Sciences to Release Fourth Quarter & Full Year 2025 Financial Results on Tuesday, February 10, 2026

Jan 21, 2026, 5:00 PM EST - 2 months ago

New England Journal of Medicine Publishes Phase 3 ASCENT-04/KEYNOTE-D19 Results Supporting Trodelvy® Plus Keytruda® as a Potential New Standard of Care in First-line PD-L1+ Metastatic Triple-negative Breast Cancer

Jan 12, 2026, 3:58 PM EST - 3 months ago

Gilead's new HIV prevention shot added to CVS's drug coverage lists, CEO says

CVS

Jan 12, 2026, 9:21 AM EST - 3 months ago

Gilead Sciences CEO Daniel O'Day: We have the most robust pipeline in company history

Jan 6, 2026, 7:00 AM EST - 3 months ago

OncoNano Medicine Announces Research Collaboration with Gilead to Apply ON-BOARD™ Delivery Technology to Gilead's Drug Candidate

Dec 22, 2025, 4:05 PM EST - 3 months ago

Gilead Sciences to Present at Upcoming Investor Conference

Dec 22, 2025, 8:00 AM EST - 3 months ago

Gilead Sciences Exercises Option to License Assembly Biosciences' Helicase-Primase Inhibitor Programs for Recurrent Genital Herpes

ASMB

Dec 19, 2025, 4:09 PM EST - 3 months ago

Nine pharmaceutical companies including Bristol-Myers Squibb, GSK and Merck agreed to lower the prices that certain federal government programs and patients pay

BMY GSK MRK AMGN NVS SNY

Dec 19, 2025, 3:14 PM EST - 3 months ago

Trump strikes deal with US drugmakers to cut Medicaid medicine costs

AMGN BMY GSK MRK NVS SNY

Dec 19, 2025, 2:34 PM EST - 3 months ago

Nine of the largest pharma companies ink deals with Trump to lower drug prices

AMGN BMY GSK MRK NVS SNY

Dec 19, 2025, 2:21 PM EST - 3 months ago

Gilead and U.S. Government Enter Agreement to Lower Costs of Medicines for Americans

Dec 19, 2025, 10:45 AM EST - 3 months ago

Trump to announce new drug-pricing deals later today

ABBV AMGN AZN BMY LLY MRK NVO

Dec 18, 2025, 8:30 AM EST - 3 months ago

Gilead Sciences Appoints Keeley Wettan as Executive Vice President, General Counsel, Legal & Compliance

notreload_ai Apr. 7 at 8:01 PM

0 · Reply

StocktwitsNews Apr. 7 at 7:29 PM

Gilead-Tubulis $5B Deal Gives STRO Stock A Boost — Here’s Why $STRO $GILD https://stocktwits.com/news/equity/markets/gilead-tubulis-5b-deal-gives-stro-stock-a-boost-here-why/cZJBRoxRIqc

0 · Reply

RadioIsotope25 Apr. 7 at 5:46 PM

Gilead loading $GILD in ADC’s they need radio ADC’s at $RADX

0 · Reply

notreload_ai Apr. 7 at 12:55 PM

$GILD buys German biotech Tubulis for $3.15B to boost cancer-fighting “smart” drugs called ADCs. Deal closes Q2 2026. https://notreload.xyz/xy/gilead-acquires-tubulis-in-adc-oncology-deal/

0 · Reply

EdwardGonza Apr. 7 at 12:54 PM

0 · Reply

OpenOutcrier Apr. 7 at 12:31 PM

$GILD (-0.8% pre) Gilead To Buy Tubulis For $3.15B Cash, Up To $1.85B Contingent - Bloomberg https://ooc.bz/l/98118

0 · Reply

55X_ROI_Q1_2026 Apr. 7 at 4:38 AM

0 · Reply

55X_ROI_Q1_2026 Apr. 7 at 4:15 AM

$SLS We are happy right now. Right Now. SLS009 Phase 2B AML-Mr data published at ASH is better than $FTSV Magrolimab Ph1B AML-Mr data published at ASH, that caused $GILD to buy it for $4.9B.

1 · Reply

trenddetector Apr. 6 at 4:03 PM

0 · Reply

TILResearch Apr. 4 at 5:13 AM

0 · Reply

trenddetector Apr. 3 at 4:11 PM

$GILD Built a free tool to help navigate cancer treatment options and clinical trials — would really appreciate feedback https://nimble-frangollo-81ff5e.netlify.app/

0 · Reply

55X_ROI_Q1_2026 Apr. 3 at 12:35 AM

$SLS this $0.71B Manipulated equity is worth $40B to to Big Pharma - the instant the Phase 3 Results are announced. - Love the ALL IN attitude - and for any new people investigating - just the "secondary asset" has direct market comps at $5B + $GILD bought $FTSV for $4.9B based AML-Mr Phase 1B data that wasn't as good as the SLS009 Phase 2B data in the same AML-Mr patient setting. a Complete Free Roll, for when the GPS Phase 3 Results are Announced. Whatever you think you know, you will get it, the positive P3 Result will Give GPS the FDA Green light to treat upwards of 40,000 AML Remission Patients Each year +100,000 who are currently IN remission. $28B TAM worth $40B to Big Pharma.

0 · Reply

TechTraderGrok Apr. 2 at 8:06 PM

Sold $GILD at $139.14 (-0.1%). From Grok: "GILD is struggling below its EMA and SMA with persistently bearish MACD and only neutral RSI, so we're closing the long from $139.37 to stay in cash after this weak bounce. " https://www.techtrader.ai/grokwall/?post=17515&utm_source=dlvr.it&utm_medium=stocktwits

0 · Reply

MaxDomain Apr. 2 at 4:16 PM

$GILD Don`t miss out on $ABVE next big move coming soon!

0 · Reply

CapitalMonk Apr. 2 at 3:48 PM

$GILD Price: $139.68 (-0.44%) Trend: Bullish Market Bias (7D): Bearish Bias 📉 Expected Range: ±0.81% RSI: 36.7 | Momentum: Moderate Volume: -76.9% vs avg Volatility: 1.35% Support: $133.89 | Resistance: $148.54 Tools used: https://www.trade-ideas.com Code: INTERSTOCK25

0 · Reply

StockTrendHunter Apr. 2 at 8:40 AM

Biotech is quietly entering a new phase—and the capital is flowing fast. The big players aren’t chasing broad, risky pipelines anymore. Instead, $AMGN, $GILD, and $REGN are aggressively scooping up smaller biotech firms with already-approved therapies targeting ultra-rare genetic diseases. That means lower development risk, faster revenue, and highly defensible niches. This shift signals a clear trend: precision medicine + rare disease = pricing power + exclusivity. With orphan drug approvals and limited competition, these assets can generate outsized margins and long-term cash flow. Smart money isn’t waiting for the next blockbuster—it’s buying proven innovation in overlooked corners of biotech. Watch this space. The race for rare disease dominance is just getting started.

1 · Reply

RobinCollins1 Apr. 2 at 8:14 AM

$GILD keeps the pressure on—extending its tender offer for $ACLX to April 24 So far only ~7.5% of shares tendered, which signals: • Limited early acceptance • Potential resistance from holders • The deal still needs momentum to move forward For $GILD, this extension is a strategic move—buy more time to secure a higher acceptance rate without raising the offer (at least for now). For $ACLX holders, the low tender rate keeps the deal in a bit of a “wait-and-see” zone. If participation stays low, expect: Continued deal pressure Possible negotiation dynamics Increased volatility into the deadline

0 · Reply

TradeTracs Apr. 1 at 8:54 PM

$GILD tender offer for $ACLX extended to Apr 24 — only 7.5% of shares tendered so far. Red flag or just slow accumulation? $ACLX holding near $114.75, hugging its 52-week high of $114.91. RSI at 81 — overbought, but deal arb is keeping it pinned. Up 80% QTR. Sellers aren't panicking yet. $GILD at $140.30, below both SMA20 ($141.53) and SMA50 ($144.33). Low conviction on acquirer side too. Watching $ACLX for any spread widening — that's your signal the deal risk is rising. Deal closes or falls apart by Apr 24. ⚠️ #Biotech #MergersAndAcquisitions #DealArb

0 · Reply

DonCorleone77 Apr. 1 at 8:16 PM

$ACLX $GILD Gilead extends tender offer to acquire Arcellx Gilead Sciences (GILD) extended the expiration of the tender offer to purchase all outstanding shares of common stock of Arcellx (ACLX). The offer remains at a purchase price of (1) $115.00 per share, net to the seller in cash, without interest, subject to any withholding tax, plus (2) one contractual contingent value right , which represents the right to receive one contingent payment of $5.00 per CVR in cash, without interest, and subject to any withholding tax, payable on March 31, 2030, subject to cumulative worldwide sales of Arcellx's anitocabtagene autoleucel (anito-cel) product exceeding $6.0 billion on or prior to December 31, 2029.

0 · Reply

TechTraderGrok Mar. 31 at 8:49 PM

Bought $GILD at $139.26. From Grok: "After staying in cash due to no clear trend or momentum following the recent breakdown, today's strong upside move to 140.34 with a solid 138.94 close on higher volume changes the technical picture to bullish, so we're going long." https://www.techtrader.ai/grokwall/?post=17416&utm_source=dlvr.it&utm_medium=stocktwits

0 · Reply

Pearl_Power Mar. 30 at 6:36 PM

$GILD nice inside candle👀

0 · Reply

OptionSamurai Mar. 30 at 2:59 PM

$GILD appears in our scan that looks for calls that will explode if the stock goes to analyst target. ✔ Analysts rating is BUY ✔ The analyst target price is 17.6% away ✔ IV Percentile is 73.0% Call 140.0, 18-Jun-26 has: 💀 Max loss of 4.9% compared to holding shares ⚖ Breakeven is 7.8% away 📈 If the stock hits the target, the call will profit 200% 🔥 See more results & create your own scan here: https://bit.ly/3lR1xIP

0 · Reply

Market Cap	173.41B
Revenue (ttm)	29.44B
Net Income (ttm)	8.51B
EPS (ttm)	N/A
PE Ratio	17.21
Forward PE	16.20
Profit Margin	28.90%
Debt to Equity Ratio	1.10

Volume	5,436,631
Avg Vol	7,255,890
Day's Range	N/A - N/A
Shares Out	1.24B
Stochastic %K	82%
Beta	0.39
Analysts	Strong Sell
Price Target	$158.86